Positive news and deals at the CACLP, with an already improved sales pipeline in place with GeneoDx, should see cash flow from prospective customers in 2 quarters, at the earliest, in my humble opinion.
So around Sept/ Oct period.
Ellume related income could be earlier, but not very likely, IMO.
This is still in time to generate enough volume to finance salaries and fixed costs, particularly since revenue numbers should accelerate, to what degree, that should be possible to evaluate after details being shared from CACLP, where Anteo will commence a full commercial launch for its products.
This could get very dynamic very quickly, IMO.
Positive news and deals at the CACLP, with an already improved...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
